Comparative Pharmacology
Head-to-head clinical analysis: PROBAMPACIN versus PYOPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROBAMPACIN versus PYOPEN.
PROBAMPACIN vs PYOPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PROBAMPACIN is a synthetic aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and preventing translocation of peptidyl-tRNA from the A-site to the P-site.
Carbenicillin is a bactericidal penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
100 mg IV every 12 hours over 30 minutes.
4 g intravenously every 4 hours.
None Documented
None Documented
4.5 hours (prolonged to 12-18 hours in severe renal impairment)
30-60 minutes in normal renal function; prolonged to 2-4 hours in moderate renal impairment (CrCl 10-30 mL/min) and up to 10 hours in severe renal failure.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Primarily renal (60-90% unchanged via glomerular filtration and tubular secretion); small amounts biliary (10-30%) and fecal (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic